UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 86

Sortiert nach

Nivolumab for treatment of progressive multifocal leukoencephalopathy in Sézary syndrome

European journal of neurology, 2020-11, Vol.27 (11), p.2373-2374

2020

Link zum Volltext

Verfügbarkeit prüfen

Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy

Nature biotechnology, 2024-03

2024

Link zum Volltext

Verfügbarkeit prüfen

Emerging targets for anticancer vaccination: IDH

ESMO open, 2021-08, Vol.6 (4), p.100214-100214, Article 100214

2021

Link zum Volltext

Verfügbarkeit prüfen

The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway

Oncogene, 2016-06, Vol.35 (25), p.3260-3271

2016

Link zum Volltext

Verfügbarkeit prüfen

Immuntherapien bei Gliomen

Best practice onkologie, 2018-06, Vol.13 (4), p.196-204

2018

Link zum Volltext

Verfügbarkeit prüfen

Hirntumorimmuntherapie – Möglichkeiten und Herausforderungen der Personalisierung

Nervenarzt, 2021-10, Vol.92 (10), p.996-1001

2021

Link zum Volltext

Verfügbarkeit prüfen

Colour homogeneity and visual perception of age, health and attractiveness of male facial skin

Journal of the European Academy of Dermatology and Venereology, 2012-12, Vol.26 (12), p.1486-1492

2012

Link zum Volltext

Verfügbarkeit prüfen

Visible skin colouration predicts perception of male facial age, health and attractiveness

International journal of cosmetic science, 2012-08, Vol.34 (4), p.307-310

2012

Link zum Volltext

Verfügbarkeit prüfen

Brain tumor immunotherapy-Possibilities and challenges of personalization

Nervenarzt, 2021-10, Vol.92 (10), p.996-1001

2021

Link zum Volltext

Verfügbarkeit prüfen

What can deliberative approaches bring to the monetary valuation of ecosystem services? A literature review

Ecosystem services, 2015-08, Vol.14, p.88-97

2015

Link zum Volltext

Verfügbarkeit prüfen

P02.07.A IMMUNOLOGICAL AND EPIGENETIC FEATURES OF RADIATION NECROSIS IN GLIOBLASTOMA PATIENTS

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii30-ii31

2023

Link zum Volltext

Verfügbarkeit prüfen

KS01.6.A Comparative analysis of the immune compartment in human glioblastoma and IDH-mutant WHO grade 4 astrocytoma reveals profound differences in microglia phenotypes

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii4-ii4

2021

Link zum Volltext

Verfügbarkeit prüfen

OS06.4A Identification of T cell receptors targeting ZFTA-RELA fusion-positive ependymoma

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii9-ii9

2021

Link zum Volltext

Verfügbarkeit prüfen

KS01.3.A Tumoral MHC class II expression in gliomas drives T cell exhaustion

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii3-ii3

2021

Link zum Volltext

Verfügbarkeit prüfen

P06.05.A INTRACEREBROVENTRICULAR TCR-TRANSGENIC T CELL THERAPY TO TREAT GLIOBLASTOMA (INVENT4GB)

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii46-ii46

2023

Link zum Volltext

Verfügbarkeit prüfen

P06.12.A NLGN4X-SPECIFIC TCR T CELLS TARGETING EXPERIMENTAL GLIOMAS

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii48-ii48

2023

Link zum Volltext

Verfügbarkeit prüfen

OS12.4.A MHC class II-restricted transgenic T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (Supplement_2), p.ii15-ii15

2021

Link zum Volltext

Verfügbarkeit prüfen

P01.140 An H3.3K27M long peptide vaccine induces expansion of specific CD4 and CD8 T cell clones in a patient with progressive H3.3K27M-mutant midline glioma

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (suppl_3), p.iii264-iii264

2018

Link zum Volltext

Verfügbarkeit prüfen

KS01.5.A LATE BREAKING ABSTRACT: LONG-TERM FOLLOW-UP OF PATIENTS WITH NEWLY DIAGNOSED IDH-MUTANT ASTROCYTOMA AFTER IDH1-VAC TREATMENT

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii3-ii3

2023

Link zum Volltext

Verfügbarkeit prüfen

P04.62 The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling

Neuro-oncology (Charlottesville, Va.), 2018-09, Vol.20 (suppl_3), p.iii293-iii294

2018

Link zum Volltext

Verfügbarkeit prüfen

PL01.4.A LATE BREAKING ABSTRACT: A LONG PEPTIDE VACCINE TARGETING THE CLONAL DRIVER MUTATION H3K27M IN ADULT PATIENTS WITH DIFFUSE MIDLINE GLIOMA

Neuro-oncology (Charlottesville, Va.), 2023-09, Vol.25 (Supplement_2), p.ii1-ii1

2023

Link zum Volltext

Verfügbarkeit prüfen

OS09.9 Identification of IDH1R132H-specific T cell receptors from glioma patients and from MHC-humanized mice

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii20-iii20

2017

Link zum Volltext

Verfügbarkeit prüfen

OS10.2 R-2-Hydroxyglutarate shapes the immune microenvironment in IDH1-mutant gliomas

Neuro-oncology (Charlottesville, Va.), 2017-05, Vol.19 (suppl_3), p.iii20-iii21

2017

Link zum Volltext

Verfügbarkeit prüfen

P04.04 Ex vivo expansion of human glioma-infiltrating lymphocytes alters the exhaustion phenotype of T cells

Neuro-oncology (Charlottesville, Va.), 2016-10, Vol.18 (suppl_4), p.iv24-iv24

2016

Link zum Volltext

Verfügbarkeit prüfen

OS2.3 A mutation-specific vaccination approach for Histon H3.3 K27M-mutated gliomas

Neuro-oncology (Charlottesville, Va.), 2016-10, Vol.18 (suppl_4), p.iv5-iv5

2016

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 86

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(76)
Mit Volltextzugriff
(76)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(38)
Life Sciences & Biomedicine
(24)
Humans
(17)
Adult
(13)
Biological And Medical Sciences
(11)
Computer Science
(11)
Technology
(11)
Male
(10)
Medical Sciences
(10)
Female
(9)
Animals
(8)
Adolescent
(7)
Computer Science, Theory & Methods
(7)
Biochemistry & Molecular Biology
(6)
Computer Science, Software Engineering
(6)
Oral Presentations
(6)
Software Engineering
(6)
Aged
(5)
Exact Sciences And Technology
(5)
Glioma
(5)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Nivolumab for treatment of progressive multifocal leukoencephalopathy in Sézary syndrome

Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy

Emerging targets for anticancer vaccination: IDH

The aryl hydrocarbon receptor links integrin signaling to the TGF-β pathway

Immuntherapien bei Gliomen

Hirntumorimmuntherapie – Möglichkeiten und Herausforderungen der Personalisierung

Colour homogeneity and visual perception of age, health and attractiveness of male facial skin

Visible skin colouration predicts perception of male facial age, health and attractiveness

Brain tumor immunotherapy-Possibilities and challenges of personalization

What can deliberative approaches bring to the monetary valuation of ecosystem services? A literature review

P02.07.A IMMUNOLOGICAL AND EPIGENETIC FEATURES OF RADIATION NECROSIS IN GLIOBLASTOMA PATIENTS

KS01.6.A Comparative analysis of the immune compartment in human glioblastoma and IDH-mutant WHO grade 4 astrocytoma reveals profound differences in microglia phenotypes

OS06.4A Identification of T cell receptors targeting ZFTA-RELA fusion-positive ependymoma

KS01.3.A Tumoral MHC class II expression in gliomas drives T cell exhaustion

P06.05.A INTRACEREBROVENTRICULAR TCR-TRANSGENIC T CELL THERAPY TO TREAT GLIOBLASTOMA (INVENT4GB)

P06.12.A NLGN4X-SPECIFIC TCR T CELLS TARGETING EXPERIMENTAL GLIOMAS

OS12.4.A MHC class II-restricted transgenic T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas

P01.140 An H3.3K27M long peptide vaccine induces expansion of specific CD4 and CD8 T cell clones in a patient with progressive H3.3K27M-mutant midline glioma

KS01.5.A LATE BREAKING ABSTRACT: LONG-TERM FOLLOW-UP OF PATIENTS WITH NEWLY DIAGNOSED IDH-MUTANT ASTROCYTOMA AFTER IDH1-VAC TREATMENT

P04.62 The oncometabolite R-2-Hydroxyglutarate suppresses the innate immune microenvironment of IDH1-mutated gliomas via aryl hydrocarbon receptor signaling

PL01.4.A LATE BREAKING ABSTRACT: A LONG PEPTIDE VACCINE TARGETING THE CLONAL DRIVER MUTATION H3K27M IN ADULT PATIENTS WITH DIFFUSE MIDLINE GLIOMA

OS09.9 Identification of IDH1R132H-specific T cell receptors from glioma patients and from MHC-humanized mice

OS10.2 R-2-Hydroxyglutarate shapes the immune microenvironment in IDH1-mutant gliomas

P04.04 Ex vivo expansion of human glioma-infiltrating lymphocytes alters the exhaustion phenotype of T cells

OS2.3 A mutation-specific vaccination approach for Histon H3.3 K27M-mutated gliomas

Suchergebnisse filtern